FR104E - - Google Patents

Info

Publication number
FR104E
FR104E FR104DA FR104E FR 104 E FR104 E FR 104E FR 104D A FR104D A FR 104DA FR 104 E FR104 E FR 104E
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Publication of FR104E publication Critical patent/FR104E/fr
Active legal-status Critical Current

Links

FR104D Active FR104E (ja)

Publications (1)

Publication Number Publication Date
FR104E true FR104E (ja)

Family

ID=1341612

Family Applications (1)

Application Number Title Priority Date Filing Date
FR104D Active FR104E (ja)

Country Status (1)

Country Link
FR (1) FR104E (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020203160A1 (ja) 2019-03-29 2020-10-08 日東電工株式会社 積層体の製造方法、塗装物の製造方法、接合構造体の製造方法、熱転写シート、及び積層体
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021255447A1 (en) 2020-06-16 2021-12-23 Ucl Business Ltd Follicular helper t cell profile for identifying patients with type 1 diabetes suitable fro treatment with ctla-4-ig
WO2022094391A2 (en) 2020-11-02 2022-05-05 Neuvogen, Inc. Breast cancer tumor cell vaccines
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023077129A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Tetrazine conjugates for in vivo targeted delivery of a payload
WO2023077126A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Trans-cyclooctene conjugates
FR3135805A1 (fr) 2022-05-23 2023-11-24 Idemia France Procédé de gestion de profils de service d’un élément sécurisé

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020203160A1 (ja) 2019-03-29 2020-10-08 日東電工株式会社 積層体の製造方法、塗装物の製造方法、接合構造体の製造方法、熱転写シート、及び積層体
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021255447A1 (en) 2020-06-16 2021-12-23 Ucl Business Ltd Follicular helper t cell profile for identifying patients with type 1 diabetes suitable fro treatment with ctla-4-ig
WO2022094391A2 (en) 2020-11-02 2022-05-05 Neuvogen, Inc. Breast cancer tumor cell vaccines
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023077129A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Tetrazine conjugates for in vivo targeted delivery of a payload
WO2023077126A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Trans-cyclooctene conjugates
FR3135805A1 (fr) 2022-05-23 2023-11-24 Idemia France Procédé de gestion de profils de service d’un élément sécurisé

Similar Documents

Publication Publication Date Title
US11376272B2 (en) Methods of modulating immune activity
US20210251994A1 (en) Increasing immune activity through modulation of postcellular signaling factors
JP2023509359A (ja) 鉄依存性細胞分解の誘導物質との併用抗癌療法
TW202328188A (zh) 抗醣化-cmet抗體及其用途
FR104E (ja)
EP4422693A1 (en) Trans-cyclooctene conjugates
EP4422696A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
TW202325726A (zh) 抗醣-muc4抗體及其用途
JPWO2019241730A5 (ja)
EP3950375A1 (en) Laminated body manufacturing method, painting object manufacturing method, joining structure manufacturing method, thermal transfer sheet, and laminated body
JPWO2021127217A5 (ja)
TW202325733A (zh) 抗醣化-lamp1抗體及其用途
EP4236995A2 (en) Tumor cell vaccines
AU2021368780A9 (en) Tumor cell vaccines
EP4165405A1 (en) Follicular helper t cell profile for identifying patients with type 1 diabetes suitable fro treatment with ctla-4-ig
FR3135805A1 (fr) Procédé de gestion de profils de service d’un élément sécurisé